Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

BACKGROUND: Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). The identification of a chemotherapeutic regimen that is both effective and tolerable is critical for NAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Alva-Ruiz, Roberto, Yohanathan, Lavanya, Yonkus, Jennifer A., Abdelrahman, Amro M., Gregory, Lindsey A., Halfdanarson, Thorvadur R., Mahipal, Amit, McWilliams, Robert R., Ma, Wen Wee, Hallemeier, Christopher L., Graham, Rondell P., Grotz, Travis E., Smoot, Rory L., Cleary, Sean P., Nagorney, David M., Kendrick, Michael L., Truty, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Pancreatic Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810469/
https://www.ncbi.nlm.nih.gov/pubmed/34724125
http://dx.doi.org/10.1245/s10434-021-10991-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810469/
https://www.ncbi.nlm.nih.gov/pubmed/34724125
http://dx.doi.org/10.1245/s10434-021-10991-2

Ejemplares similares